Published in Br Med J on January 08, 1977
Drug information centres: a clinical pharmacologist's view. Proc R Soc Med (1977) 1.66
Which factors predict the time spent answering queries to a drug information centre? Pharm World Sci (2010) 1.05
Therapeutic consultation: a necessary adjunct to independent drug information. Br J Clin Pharmacol (1993) 0.88
Use of a pilot drug information centre. Afr Health Sci (2011) 0.84
Evidence to the Royal Commission on the National Health Service. 2. From the Committee of Professors of Clinical Pharmacology and Therapeutics, Association of Professors of Internal Medicine. Br J Clin Pharmacol (1978) 0.75
Therapeutic consultation centres are helpful in developing countries. BMJ (2002) 0.75
Questions about complementary and alternative medicine to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive pilot study. BMC Complement Altern Med (2014) 0.75
Clinical pharmacology in everyday clinical care. Eur J Clin Pharmacol (2013) 0.75
The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol (1968) 9.44
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Evidence against adrenergic motor transmission in the guinea-pig vas deferens. J Physiol (1971) 6.27
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Monitoring adverse reactions to drugs. Br Med J (1977) 4.41
A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry (1990) 3.74
Non-cholinergic transmission by post-ganglionic motor neurones in the mammalian bladder. J Physiol (1970) 3.68
Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ (2007) 3.26
Inhibition of post-ganglionic motor transmission in vas deferens by indirectly acting sympathomimetic drugs. J Physiol (1972) 3.22
Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) (1985) 2.97
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol (2007) 2.97
Studies of vitamin D deficiency in man. Q J Med (1975) 2.94
Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol (1999) 2.78
Unexplained inhibitory action of D-lysergic acid diethylamide (LSD) on postganglionic motor transmission in the guinea-pig vas deferens. Br J Pharmacol (1971) 2.60
Impact of sociodemographic case mix on the HEDIS measures of health plan quality. Med Care (2000) 2.57
The failings of NICE. Reply from chairman of NICE. BMJ (2001) 2.55
Activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet (1979) 2.54
Clinical pharmacology in the National Health Service. J R Soc Med (1978) 2.54
Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol (1992) 2.51
Clinical pharmacology in a district general hospital. Lancet (1976) 2.47
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
Self-titration by cigarette smokers. Br Med J (1979) 2.46
The role of the pharmaceutical industry in postgraduate medical education. Br J Clin Pharmacol (1977) 2.45
The mechanism of acetylcholine release from parasympathetic nerves. J Physiol (1971) 2.45
Clinical pharmacology clinics in general practice. Br Med J (1977) 2.28
Changing patterns of self-poisoning in a UK health district. QJM (1996) 2.13
Doctors and the drug makers. Lancet (1984) 2.09
Use of split-skin grafting in the treatment of chronic leg ulcers. Ann R Coll Surg Engl (1995) 2.06
Extending the role of the community pharmacist. BMJ (1991) 2.05
Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis (1998) 2.03
Motor transmission in the vas deferens: the inhibitory action of noradrenaline. Br J Pharmacol (1970) 1.97
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ (1997) 1.96
Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol (1979) 1.95
Alcohol and drug use in UK university students. Lancet (1996) 1.94
Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J (1980) 1.87
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol (2000) 1.84
Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) (1984) 1.83
Clinical pharmacokinetics of propranolol. Clin Pharmacokinet (1979) 1.81
Review of yellow cards--1986 and 1987. Br Med J (Clin Res Ed) (1988) 1.81
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
[Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands]. Ned Tijdschr Geneeskd (1995) 1.79
Letter: How do doctors learn about drugs? Lancet (1975) 1.78
Anticoagulants in venous thromboembolism. BMJ (1988) 1.77
Evidence for the release of two atropine-resistant spasmogens from Auerbach's plexus. J Physiol (1970) 1.77
Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol (1977) 1.76
Benzodiazepine overdose: are specific antagonists useful. Br Med J (Clin Res Ed) (1985) 1.75
Lidocaine plasma protein binding. Clin Pharmacol Ther (1980) 1.74
An inhibition of post-ganglionic motor transmission in the mammalian vas deferens by D-lysergic acid diethylamide. J Physiol (1973) 1.72
Psoriasis and cancer. Br Med J (1979) 1.71
Inhibitory effect of clonidine on a peripheral adrenergic synapse [proceedings]. Br J Pharmacol (1976) 1.69
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1987) 1.69
Adenosine stimulates respiration in man. Br J Clin Pharmacol (1985) 1.67
New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol (1998) 1.67
Drug information centres: a clinical pharmacologist's view. Proc R Soc Med (1977) 1.66
Safety of late acetylcysteine treatment in paracetamol poisoning. Hum Exp Toxicol (1990) 1.65
Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med (1985) 1.65
Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Br J Clin Pharmacol (2001) 1.63
Should intake of carbon monoxide be used as a guide to intake of other smoke constituents? Br Med J (Clin Res Ed) (1981) 1.63
Predicting patients' warfarin requirements. Lancet (1977) 1.61
Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) (1984) 1.57
An inhibitory action of histamine on the guinea-pig ileum. Br J Pharmacol (1970) 1.57
Phosphate enemas in childhood: cause for concern. BMJ (1991) 1.55
Long term use of transcutaneous electrical nerve stimulation at Newcastle Pain Relief Clinic. J R Soc Med (1992) 1.53
A proposal to standardize terminology for weak D antigen. Transfusion (1992) 1.52
The plasma protein binding of basic drugs. Br J Clin Pharmacol (1986) 1.49
Medical experience in nuclear submarines. J R Nav Med Serv (1971) 1.47
Intravenous salbutamol and cardiogenic shock. Lancet (1972) 1.46
Effects of peripherally and centrally acting analgesics on somato-sensory evoked potentials. Br J Clin Pharmacol (1995) 1.46
Accidental hypothermia treated by extracorporeal blood warming. Lancet (1967) 1.46
Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) (1987) 1.46
Low prevalence of hepatitis B in mental handicap hospital. Lancet (1989) 1.45
Liquid ecstasy: a new kid on the dance floor. Br J Psychiatry (2004) 1.44
Hospital prescribing and usage of hypnotics and anxiolytics. Br J Clin Pharmacol (1991) 1.44
Atropine as possible contaminant of comfrey tea. Lancet (1989) 1.43
Reducing arthroplasty costs via vendor contracts. Can J Surg (1999) 1.43
Geographical differences in adverse drug reaction reporting rates in the Northern Region. Br J Clin Pharmacol (1991) 1.43
A randomised, controlled study of uterine exteriorisation and repair at caesarean section. Br J Obstet Gynaecol (1999) 1.41
Community exposures to chemical incidents: development and evaluation of the first environmental public health surveillance system in europe. J Epidemiol Community Health (2000) 1.39
Spontaneous periodic hypothermia: diencephalic epilepsy. Br Med J (1973) 1.39
Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. Q J Med (1986) 1.39
Opioid peptides. Br Med J (Clin Res Ed) (1984) 1.38
The effect of intravenous aminophylline on essential tremor. Br J Clin Pharmacol (1997) 1.38
Lipid emulsification after implant rupture. Br J Plast Surg (1999) 1.38
Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J (Clin Res Ed) (1985) 1.36
Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol (1979) 1.36
Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med (1980) 1.35
Clinical pharmacology. Adverse reactions to drugs. Br Med J (Clin Res Ed) (1981) 1.35
Lignocaine disposition in blood in epilepsy. Br J Clin Pharmacol (1981) 1.35
Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry (1998) 1.34